ImmunityBio, Inc.
NASDAQImmunityBio heads into the week with a striking combination: a short score pinned above 83, borrow availability running well below normal, and a founder-CEO who controls nearly two-thirds of the company's shares — leaving a thin tradeable float caught between persistent short sellers and an unusually concentrated ownership structure. The lending market tells the clearest story…
IBRX utilization surges to 94.21%, highest in 52 weeks, as short availability plummets to just 7%.
ImmunityBio heads into the week with a striking combination: a short score pinned above 83, borrow availability running well below normal, and a founder-CEO who controls nearly two-thirds of the company's shares —…
ImmunityBio has hit a new inflection point this week — the borrow market, already tight heading into the June 9 earnings release, has effectively run dry, even as the stock dropped 7% over the past five days to…
Snapshot as of 19 Sept 2026
IBRX enters its June 9 earnings release with a lending market that has rarely been looser than "very tight." Availability has dropped to just 6.2% — meaning fewer than seven shares remain available to borrow for every…
ImmunityBio heads into its June 9 earnings report caught between two opposing forces: options traders have turned sharply bullish on a three-day basis, yet a deeply entrenched short position covering more than a third…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IBRX — free to start on ORTEX.
Sign up for free →Open IBRX on ORTEX